Atreca Inc - Ordinary Shares (BCEL) 29 Mar 232022 Q4 Earnings call transcript

Thank you for standing by. Welcome to the Atreca's Fourth Quarter and Year End 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]

hand Gray. over to Investor Head like Alex Relations, now the to call of I'd ahead. go Please,

Thank you, XXXX thank ongoing pleased webcast, operator, and updated Phase to today. joining including ATRC-XXX. host We Xb us trial our from year-end data conference of and you call our to those

the John Officer. prepared Dr. the is Bishop, Tito Chief be line Officer; CEO; and Serafini, Also Founder; Chief Financial Joining me will Orwin, Atreca Philippe for Strategy Gould, Q&A Dr. Scientific Chief Stephen on remarks are Chief who Cross, Dr. Officer and Herb session. Medical Officer during available

For release of that today's note posted and those included via we part can which Relations following Presentation ir.atreca.com. presentation. slides link the accompanying be to the section at replay viewed as today's phone, joining program, by the on Investor available earnings the are our I'd site, webcast presenting be our of our webcast website of and IR live slides and archived An Events will in

today's based differ statements on making a and current forward-looking and our may call, materially. statements actual number uncertainties, These subject to results are be expectations. we During significant of risks will

required correct. can no information statements no and are that law. Exchange to these disclosure most made We description available file assurance and our Form statements and today, be We risks except these a XX, reports we financial refer the statements, duty XX-K prove Securities based that Commission. of give and affect forms X-K the to undertake will in as may recent on please factors update currently All by For future March our results the of XXXX, accompanying our to with business, the us. as on could that slides, XX-Q and

over to it I'll Orwin. John turn now

John?

ongoing in line On and and pipeline. our will from combination I provide will Q&A. upcoming the evolution. overview then and preclinical cohorts ATRC-XXX for discuss on you, Stephen opening and before platform monotherapy the Thank Xb today's pembrolizumab discovery trial, then present Phase its provide will milestones will call, our Tito an update our our an Philippe data financials of Alex.

Slide on pipeline. is of and our platform X a overview Shown broad

platform access binding reminder, tumor be us Atreca found has novel that enables traditional that antibodies would to targets to a As proprietary via novel discovery approaches. a unlikely

the Tito As the a in platform, more anti-tumor later, we'll tumor the active generated in in to with continued has targets From believe efficiently. we've promising as the invest by development their enabled activity which our platform will Xb we've antibodies and and to potential. therapeutic ongoing platform, discuss antibodies detail, targeting trial, durable ability find identify demonstrated which led validates ATRC-XXX, us identify Phase has to we discuss more pipeline robust the of of which

surface drug an glycan RNA-binding partnership engager strategy as recognizes our We a T-cell programs, protein by end a as well which specific provide plan novel year. a cell clinical preclinical is including an APN-XXXXXX, of and promising to decision X tumor development on APN-XXXXXX, as as go/no-go for ATRC-XXX, a We're the update Xencor. advancing for targets antibody and advancing multiple also target is which including advancing with conjugate, this Phase in

from oncology programs candidates to expect and XXXX. additional We begin in year clinical later clinical for nominate studies both programs this

its updated to the we Tito I will evolution platform review ATRC-XXX our pipeline. now turn briefly it and data and preclinical before discuss discovery over to

response the Thanks, active an approach X, John. immune in our novel which novel generated Slide is antibodies binding to us pipeline targets. guides by On

system patients is with starting tissue. whose blood immune On samples the left, top our half adaptive begins of the the tumor on attacking from slide, approach

defined in by analyzing being that chains patient type we of importantly, to generated natively the of Moving a a antibodies fidelity, light time. active generate samples, response, immune B that are those the response access the that high and to right, that immune paired at and cells the via in heavy single point

Moving sequences silico further the and select synthesis antibody again in right, then evaluation in we those for analyze to and laboratory. the

synthesized line simple it in the If cytometry, these vitro, antibodies blinded by we have tissue of screening other response the comes flow question, to By from normal which this the is one does surface non-autologous a antibody. binds yes, tumor does tissue. do a also tumor ask over antibody and patient tissue we hit and so a of cell answer is as of preferentially tumor immune the that antibody measured patients

slide, half moment the in a in I'll order into and antibodies clinical turn detail. them to further we develop as evaluate then in more describe On of the bottom our hit candidates

during families the analyzing evaluation clonal approach enabled Slide all antibody the works. as information focus behind analyzing slide parents, disappearance, for the circled generate purple on antibodies to these, was families, the cells response. clonal by In dots. in those approach tumor treatment showing this in biology this that generated tissue laboratory. time particular X. and patient as as its plasmablast of at and more This figure. after why antibodies four patient Moving one to attacking by By directly, a groups and and the we're and point particular green, treatment successfully size, immune These families from such processed of generated provide B-cell colored sequences antibodies before blowup, key yield of partial being middle green, Plasmablasts of in our we slide a on illustrates derived select antibodies these being uniquely persistence, from that the the progenitor dots, as plasmablast, B The further two our we antigens generated well we in the from their response. as in points case are is we've single antibodies

at proprietary around composition processes. in protected the matter analysis of bottom noted our is silico as binding the goes of non-autologous tumor granted the method often beyond time typical approximately claims the jurisdictions screens. in use of synthesized more antibodies primary of slide, our by worldwide, tissue multiple And which claims Our in delivers XX% approach

the acquire types. over discovery Moving X. few studies in now platform samples run decade approach. cancer in execute a a points. left, X,XXX on order we non-interventional clinically XX nearly Slide a This repository on tumor to donors, own and our have over our Starting we patients, to with we over from built representing key on I'll sample from have that focus annotated is generated samples valuable XXX the

then then we turning leads these plasmablast and antibodies. tumoricidal histology evaluation activity, requires I right, And in epitope further antibody, antibodies that select use the a Moving hand active vitro these target. for has and target described flow moving provides bound analysis in manner their right, the to into antibodies by in to positive would identify data, analyze we generate histology And antibody that eventually but that by about be most and which briefly generate, also weaponization samples the on work for the information cytometry with suitable. to that

suitable right its again. weaponized a we assuring for clinical optimizing safety work criteria, profile identifying and clinical biomarkers If further final by our by and that format antibody meets an candidate sequence use during antibody by development. Moving a a then suitable from engineering to generate

Slide to X. Moving

advances I'm over the sample left, Starting this the to we've new to highlighting do, more achieve few salient we've expanded and top to on pipeline that sites of assets. efficiency greater time and collection a deliver the platform evolved we've promised made. we slide, As On indications. our

our automation operating more below histological that, enable to we're analysis incorporated of and targets. now antibody down, scale evaluation our Moving and our flow has an normal tumor now expression at industrial of cytometry speed. tissue And earlier

Moving measure to the implemented top we've in to proprietary high-throughput assays weaponization. right, the activity to vitro relevant

existing weaponization functional genome generate platform. to had a unbiased target optimization And represented in down, multiple but and not we were biochemical remove implemented that identification added bottleneck lead Next genomic to finally, again, candidates formats. methods in structure-based screens exclusively, to our

stage which X, and to listing ATRC-XXX, Slide discuss review our you a clinical our generated asset, detail. On will we'll Slide current been assets. have clinical Moving XX, of pipeline, our see the of There's all Philippe assets preclinical our stage platform. later which by in quickly

hear the then You'll pipeline assets. preclinical Stephen about other from currently

to over Philippe. it Turning

Slide combination enrolled Tito, March pleased study Phase study were from we're The of presenting XX our top XX XX-milligram Xb the the to of share today. patients at you, objective information Thanks, level includes and the to of per ongoing treated in highest is including be since update. the them continues arms which safety, thank 'XX joining On am evaluate today, and summary in ATRC-XXX everyone, of primary call kilogram. monotherapy is the I and trial. ATRC-XXX well update line for XX tolerated dose that to the

activity target. antitumor see express patients continue We that to in

types across pretreated heavily and and we're to are in excited with this durable disease and we heterogeneous monotherapy report cancer seeing participants stable therapy. combination responses in that treated group, Furthermore, participant several

briefly data, three will of characteristics the set trial the in the participants next design, analysis and discuss I review the we slides. Before the treated baseline

and multiple is and in when for The and trial additional indications across safety basket expression. of activity, or to three monotherapy ATRC-XXX including an tumor escalation studying reminder, ATRC-XXX patients or as expansion. as by types. objective administered The followed objectives, following response of began a Initial monotherapy pembrolizumab determining Slide had patients analyzing combination, with the cohort anti-PD-X on included therapy. with as target this As enrolling every regardless PD-LX XX, of key or non-satisfactory progressed is trial shown weeks tolerability with target patients clinical physician, the treating a primary the measuring or in determine opinion the expression achieved every three administered who in weeks, trial two combination the a dose of

data started respond, level at expression early Having XX-milligram escalation from dose expression. participants we to X dose kilogram. every kilogram combination dose to now To target completed we have expanding milligrams and the monotherapy treated to appear of per levels the amended ranging we're likely cohorts. protocol enrollment X.X based enrich trial, date, for the per discriminate when year, both three-week the and Last a at target XX patients to on suggested phases

to overview characteristics Slide enrolled XX is baseline participants on of an the study. of

of the having As status February XX age participants monotherapy XX cutoff performance of of the X median X. participants most three-week on on The was overall, in XXXX, XX ECOG with schedule, had arm. enrolled combination with two-week the XX, schedule an years data a and monotherapy XX

or how heavily see can patients the the of in a participants and median across were types. in half majority It note lines to cancer very distributed is X therapy. disease have are study prior to study or received have with disease important to Nearly progression metastatic of enrolled PD-LX as the prior arm, pretreated that patients had of response You on enrolled agent of the exposure or more experienced prior for with And patients treatment. per therapy to checkpoint those PD-X had following all inhibitor. an combination the one enrolled and protocol, unsatisfactory a

On like the XX, Slide one on Beginning enrolled data would sets safety, today's dose XX at all results I the include pertinent today's with used participants to least ATRC-XXX. study will received who of to presentation. in describe

X, presented consider the cells studied kilogram, be these the milligrams immunohistochemistry XX X on analyses, and in focus to pharmacologically interim XX for H-Score correlations activity target per kilogram large we a activity, composite the at to overall evaluable XX monotherapy expression comprised of XX dose H-Score with and RECIST these today. Although But as XX who as were are defined response at doses focus there evaluable treated the and for Of will and the of we be best for were evaluable XX and dose. with number a enrolled a for When of or by were expression the that XX target doses who analysis expression. at the combination patients will score pembrolizumab. target XX-milligram target for proportion levels, expression. we examining is either intensity Participants positive subjects, clinical the per

X With the monotherapy we present population therapy. these who overall that results, separately will the from individuals results includes received combination

H-Score assessable of and by type. on Slide a XX distribution overall participants response for Presented cancer is

XX to As specific see, you from enrolled types of number zero. the tumor with subjects can range

make for the difficult development inferences decisions. insights tumor important a to indication. close cancer specific it to such, it type of of we believe numbers additional although the provide small the for we sufficient continue getting future types, As enrollment is activity in And to study and inform are about or ATRC-XXX numbers some conclusive

toxicity the a received the pattern common left Moving bars remains at or Of expression. to to be and for and the treatment participants profile relationship no the were on with dose events continues observed, of the tolerated. a events incidents nor as of reported these determined with severity events and The or who enrolled the Well, interest well on to there grade and particular adverse ATRC-XXX. adverse adverse adverse nausea treatment with adverse ATRC target between fatigue X adverse events Slide events to events dose X most blue of be of shown and XX. the were right. XX with there adverse by events with least X, dark ATRC-XXX, serious suggest pain, events most to treatment-related adverse related no treatment-related

temporarily, without abnormalities, fatigue X a my liver the was grade two grade had a come Only X and grade one, included day participant cycle who X the were a reported and drug-related X toxicity. comments. including tachycardia, AE dose and off X AEs complication. The of leading each that No as one. reaction in the had restarted one Others related, was noted obstruction a grade a patients included an patients protocol, potentially managed treatment infusion experienced to interrupted interruptions. as study headache AE on obstruction. to grade the laboratory small has infusion small These X intestinal due X intestinal per earlier grade was function dosing nausea, instance, to

activity XX. control observing to predict to cutoff Moving once supports probability disease Slide ATRC-XXX. or response assessment the a tumor The of to of for use the interim again H-Score

XXX. using target an a analysis an the based X or greater target of at negative noted H-Score on positive a correlation range to H-Score control, end a prior to CAP-CLIA As equal previously, implies maximum can of response Based is score to showing or H-Score the the H-Score immunohistochemistry cutoff from expression disease obtained assay, to XX. H-Score

bar whose graph, is who control therapy target. below bar the tumor XX% patients contrast for an H-Score achieved left patients XX. tumor XX% right similar a This monotherapy, and of to in has on disease treated yielded patients graph their The expressed the received On combination result. includes if with the

XX, there’s associated antitumor Slide assessing another activity way target of On expression. with

looking treated whose and patients we Here, right, also with a for monotherapy the tumor time patient are individual treated the on includes at shown over Those combination left; H-Score. on those graph has are with the data low therapy.

disease and days XXX most thereafter. here, progression month after past going therapy. patients' had experienced occurred XXX progression disease first As early, is shown disease Only protocol initiation following days soon of the all X soon patients at stable or

In to have for we control. had an that PFS to documented monotherapy XX reduction disease protocol lasted the this and of who XXX That XXX bottom XX% have therapy is size non-small-cell reported XXX. On response bottom the tumor of of past patient that had the was those XX blue light those greater had had response patient's to and H-Score H-Score with initiated achieved durable see patients study day in durable can the lines. study. patient's we the to we And a continues combination The XX cancer that those CR therapy. the we lung right, curve objective can their the assessment tumor on the This achieved is H-Scores and Including of tumor patient PR. lines melanoma protocol them at scores Slide day after shows low of most remain following previously initiation previously had are an recent compare at day, on reported at XX, XXX received with days to blue Several patient that target a for therapy. see a the more greater well with days. than or of patient having with there number dark in the experiencing we cohort,

patients small of on positive. observed and XX response target Slide with ATRC-XXX, for whose by pembro the cancer with or tumor all type focuses treated combination durability a therapy in was tumor

As cancer, head documented patients seen and lung depicting types, colors activity cancer, shown including is type, neck as the by as XXX. cancer multiple day different who progression-free study durable line cell well different at across cancer had breast cancer non-small melanoma, survival colon tumor

H-Score in the looking waterfall Slide tumor shown Another XX. by of plot and the way activity type is antitumor at on

bars. On cancer patient expression the with the are who on patients her size increase shown lesions, bar except is graph. in the low-target target reduction the in of solid tumor ATRC-XXX to This size in shown who a patients bars. receive in the higher Those ovarian with alone therapy combination graph, expansion are one left the had Patients cancer. right in hash contrast a of experience target who bar small whose had for received

the hash cohort, had solid several we tumor and combination in monotherapy reductions the both the patients therapy that Here, bars; see cohort, bars. the

Slide progression-free a for survival of H-Score. patients measuring a analysis, treated is Kaplan-Meier function XX as

dark On received in or combination right, therapy. on monotherapy; XX the H-Score patients than left remains in a with time. the are early the lines. light over Patients XX the treated than survival The and progression-free Kaplan-Meier patients with separates analysis blue an the patient the separated at monotherapy who line have a days less of greater with includes XX or curve longer H-Score

For with for to therapy. of ratio negative hazard all the difference patients that similar positive is and the ratio the cohort, ATRC-XXX, patients. receive also for X.XX the And is who combination observed those includes monotherapy hazard treated target target

Of curve representing for target hazard study event, experienced patients an difference not on protocol have and therapy. ratio positive and negative the the receiving who line the is interest these still small X.X are patients on vertical patients. Here, of remain is target the

tail at survival of some the progression-free you patients have can see, dark As days XXX curve. end passed the

to that has it This and continues Now of Phase data Slide most standard care. part, continues trial, and This to XX. steps the the for summary on next moving no dose update, patients we data the with in enroll kilogram and well have, exhausted Xb per to a ATRC-XXX tested. up longer this data with associated DLTs There survival XX-milligram is progression-free level were be cancer. patients are with to to target ATRC-XXX update expression appears be tolerated. learning What is that

durable early need nature on cancer of these need current While seen efforts patients. and to it disease responses. across recruitment to do the types, too enroll tumor and underrepresented several our types patients so, was quantify is properly qualify will additional to focus across will To control we

past pembrolizumab XX-milligram closed combination with start-up and sites and We the target expression at additional the the monotherapy, continue new In at cohorts. to the X, focus based study dose with have in in months, kilogram enrollment X both we we on per in sites opened X several activities. contracted

In addition, undergoing feasibility. we have X sites

a total are of to forward, to Going expected and centers the XX participate study. contribute

additional feedback, All we investigative some addition, to with and these pandemic. eligibility adapted the In patients to instances, work year-end tumor clinical are new restricting positive. failures targeting issues study. seen staffing to based by centers already enriching Overall, on for have XX not on post increase whose unexpectedly, and are recruitment are due for because target expected protocol help to to continue across criteria expression, XXXX. in enrollment activities That screen distributed target overcome make have we to XX adequate to patients decisions said, the go/no-go specific are we indications enrollment we

we seen year-end, data further line development expect decision for by paving the have our us should expectations registration screen with a go/no-go path are we recruiting commercial define opportunity way failures additional to of target ATRC-XXX ATRC-XXX. position for for already well determining The Finally, a collect in prior to improvements. enable to The efforts

pipeline I our will it preclinical now Stephen to to turn over discuss program.

towards I'll our oncology late you, three review lead nomination. Thank of programs Philippe. candidate moving now

Slide on exciting XXX. highlighted we're but with recognized address to a subsequently we are platform. one antibody conjugate as an been methods. is standard long aberrant that targets of this has our is glycosylation ADC class anti-glycan cancer, of referred a antibodies hallmark of as growing to antibody that This as uncovering has difficult or been through of novel a number advancing anti-glycan XX drug antibody XXX tumor-specific is first The as

molecule tumors and high both and As currently with I'll an active the candidate and XXXX. that of show nominate is drug portion on target to We're yield candidate and uniform vitro in to with a binding a by linker ADC, you, portion clinical for we the vivo. late colorectal in cancer antibody XXX on the IND displays -- an prevalence both optimizing as expect selective year-end

this this and all The the shows plot XX the bar cells tumor for colorectal XX% uniform staining in of very epitope. i.e., can to exhibits essentially I Slide cancer. of why in where the X+ in right XXX strong the are antibody. And hope greater is that left staining so top positive we're immunoreactivity, images X+ you about than excited appreciate

in pancreatic, We uterine, also cancer a prevalence cancer. esophageal with see lung several gastric high including in prevalence lower and indications,

normal we to antibody. Importantly, cytoplasmic we in the normal slides staining immunoreactivity membranous share highest I'll fresh in is The not data XX detect on the do the suspect tissues. in moderate not stomach, from coming accessible frozen is tissue that signal which

to On cell you tissues. and abundant the and other cancer, on to XXX from to the Slide of activity XX, that levels high in binds can cells NUGCX, immunoreactivity see consistent screened for case cytotoxicity the tissues, XXX express We shown gastric leads respectively. that not target and low-to-moderate and highlighted LoVo blue from of derived in colorectal these lines in those with derived in right. ADC

the formatted maturation that Auristatin is Xenograft expresses comparable as see payload a using level relevant model right, based can staining can cancer to of you a a in XX, of But be model. to an human model antitumor activity dose-responsive Slide XXX This shown after LoVo relatively when the a what dose high before in ZymeLink linker leads found therefore affinity any level single to as On target. system. is and ADC

per in mice up been studies PK initial as explored XX dose finding. tolerability been tolerated has also is well and in has the in loss to also this fact the without tolerated ADC weight both rats. Importantly, that mgs Auristatin single XXX ADC. human an again rats has ZymeLink The or in XXX histopathologic and that note in tolerated body staining been pointed to out multiple moderate both is with the kg should in not target well observed species mice ADC the intracellular suggests earlier of that I stomach in is pool accessible cytoplasmic both payload. the and I

not flow BXGALNTX genes two well glycosyltransferases, failed the essential sense a arrays had level two and Moving had fucose feature fucose RNA transporter. to tissue, a interesting first XXX we as binding, tumor-specific normal didn't we were we antibodies now expression that genes have being of mentioned, such makes substrate. approach. this point of explain this identified FUTX, now near positive one the genes line. looks antitumor expression protein as At intriguing knocked antibody a are the the and glycan to required a know the out to to a FUTX Slide when project, Attempts deorphanize Tito requires antibody the using largely which at absence the immunoreactivity and in whole in The for for Three but tissues. target. with cell standard screens genome XX. a glycosyltransferases CRISPR And very fucose one as transporter assess and as were point. of binding the at or in context the activity, as in-house, was Interestingly, Using approach, approaches co-expressed, we XXX CRISPR enabled individually they XXX as of we in assayed with which this knockout helps commercial

on target what the a shown the of that at is confirming in XXX. by a shift these co-expression, required these suggests right binding did are that are them required were in enzymes required in surface, the Based expressing to biochemical cell the dramatic right through we the likely these substrate flow glycan Upon saline specificity express two to the means. We cytometry validated this for two on enzymes, and this for plot present glycan that not understand least context. structure enzymes

XX. growing to XXX our alluded discovered number the that anti-glycan platform. fact of is Slide of to Advancing by a I antibodies being one

anti-glycan In for the we are target the fact, have half antibodies which identified antibodies. of

to help cell and underexploited intercellular on uncover positioned that The the late surface. uniquely Our course, this of of normal the one lead antibodies. platform, platform asset, XX. mislocalization highlighted good Slide XXX, is emerged of the also is thing targets, our A to antibodies to is potential this has the identifies next of class targets of example protein

recognizes XXX an normally stress the engager the in the lead surface in collaboration nucleus, Xencor, on advancing binding as taking clinical the but XXX to cell via CDX is potentially is sequestered preclinical bispecific RNA granule. cell development. in mislocalized where protein is T that with is the tumors Atreca and

a nominate submission are IND to XXXX. targeting early by year-end candidate and expect We by an clinical

the anything as the to similar In from XX, Slide this from however, XXX antibody anti-glycan activity. Xencor's using On engager case, of XXX, cell a shows antibody form XmAb preclinical CDX native patient -- straight the T we anybody platform. bispecific

against in optimizing in which enhance the or match to in study, stasis target to beat in positive orange. the cancer prostate use control a potency model on currently We're the bispecific blue further positive cancer shown As the leads line. a tumor the cell left, PSMA, T prostate the xenograft to direct well-known target XXX the shown specific antibody is

and blood. more to can interferon-gamma of effects you details part expansion molecules for action, expected as evidenced robust molecule pharmacodynamic that of mechanism Slide to this of which immune described advance XXX are with levels Xencor, right, positive is an by see the activation leads the collaboration the the with of in first On XXX on increase including plasma our in CDX detail XX. T-cells as in in

XX% two and targets against partner each platform. antibodies for up of will Atreca using In sharing CDX their and select XmAb mutually with programs antibodies further joint bispecific profits. engineer this development The provide will Xencor and collaboration, will novel to two the commercialization costs companies

of partner each independently. the programs, to joint allows the While to lead pursue agreement up company two programs one will each

targets Slide XXX I oncology last which types. antibody, in XX. our on tumor a range epitope The a a oncology is EphAX, well-conserved novel is will proximal overexpressed membrane lead highlighted on review anti-EphAX is of validated that target

weaponization a various evaluating to antibody where We ADC in we've active. CDX variants range Previously, series in vivo activity of advanced schemes of have we based with and are a an observed. format variants affinities engager a variant as in antibody have these and the cell high-affinity now on EphAX broadly generated they're T tested

Moving to for our Slide which the an at are molecules We're earlier molecules from XX. platform, I you stage. you excited today. hope highlighted the coming excitement share I about equally about

at believe investments the the Tito implementation the beginning oncology target of across made the CRISPR believe development made positioned discovery on Atreca screening, platform, targets. We platform to common is capitalize well eliminated especially novel identification As we mentioned bottlenecks even of our have with and of and around presentation, productive. the more we've

Finally, we licensed not development Atreca to Gates antibody the in Institute, antibody, malaria an an version of those file the wish designed infection. on and including exciting antibody preparing IND is Medical pipeline endemic molecule, U.S., to opportunities, is which rights anti-malaria Europe parts Slide discovered Asia product to year. with engineered for ATRC-XXX The retains an ATRC-XXX regions. XX. Research this potential is of Atreca malaria Atreca's to prophylaxis another asset prevent an while highlight internal

over And with of provide an overview and discuss John it financials IP. that, back and to our to I'll hand upcoming our milestones

XX Slide On milestones. Stephen. of upcoming is our you, an Thank overview

year next a are planning and and go/no-go Phase we studies begin Phase data As Philippe for updated development this to later X of noted, ATRC-XXX decision potentially X provide year.

and XXX are behind discovery in this targeting are efforts generation to early programs the lead and side, On respectively. XXXX and the nominate clinical late ongoing. we expect XXXX, later XXX early-stage those, year in candidates preclinical our INDs and And

to to file IND continues ATRC-XXX advance MRI Gates this is an year. Finally, expecting and

financials Turning to and addresses property. This Slide XX. intellectual our

of the cash we is to operations year, this and of in fund year. end XX which As through December had last investments, million of equivalents expected $XX.X

a and related as Atreca's patents assets. critical covering ATRC-XXX platform have covering discovery with position with IP applications well aspects issued We strong as of other antibodies pending pipeline

today's our like trial concludes investigators to again thank webcast call participants staff as and That prepared joined remarks. We'd well the their everyone who research and families clinical conference as Thanks to sites. and today. our at

open could line Q&A? operator, you the With that, the please for

Rao [Operator Divya Instructions] of comes of Cowen. from line question the first Our

of percent say follow-up, change what patients, you that And terms patients as trying Just many you're on in? enrich the in guess maybe does enrolled of when based not eligibility as I experience, fit that patients your how that that criteria? then high you're a for to would indications seeing H-Score is

Philippe?

you. thank Well, Yes.

So in some assessments as we the you done preclinical in of assessment had prevalent program, microarrays. know, the

depending at tumors we're on in XX% that target indication tumors. is observing were What we're trial previously. the the between looking we similar seeing data of And had we target. we're that. are consistent assessed the with had of the somewhere indications, we presence microarrays expressing in in these tumors that expressing all the across that of the to part, these the prevalence which on of looking And It's neighborhood most about the to we're for XX% So clinical looking that XX% the generated tumors target.

Roger line of from comes Song question next Our of Jefferies. the

A couple from us.

the of therapy is one for lines. care or what first patients? to the the So us whatever to you expected PFS conceptualize population have this median help is prior this available standard you X in from or those patient, just Can

Yes.

would looking it for Roger, indication you example. some as cancer aware, as another you're on patients, lung be be may So cancer, breast such depends which at

would we occurring. of And you some other now begin to I as time where are and the have like shorter standard care, from know, lines time gets observe of to some cancers, of survival As the see melanoma you where advent with seen think There indications exhaust well, immunotherapy, can progression-free you longer disease. period you expected therapy. with that. as having subsequent shorter individuals progression-free colorectal survivals with

-- at, with individuals. with tend pretreated. looking patients for to also the these already for were think in I we heavily our predicts performance the which they an have part They status are of study in that come most

looking anyone them, think think for I I data, would at the note the past it's mark. to important that so And go six-month

I at. PFS X is PFS think equally the at interesting may an to look for also months important of indications those at be The landmark. some months four

patients and the Yes, about of care. heterogeneity Roger, I of could the certainly standard of more probably sort before just have we that, types the different conclusions efficacy with to think or really of draw these and how activity we're I compares seeing open-label I add it nature that tumor to that given trial, think patients, need we the the

are responses fact by seen we do patients are I and is where disease see have that where in we targets. encouraged more expressing the who think we the control primarily context of

X function that's whether need hope we're or in to encouragement where to that and some what and we're year to have make us we'll give ATRC-XXX. ATRC-XXX. real Phase continuing and does that seeing really clearly, why a sufficient a a patients, to the centers, additional data is decision position this But So of go to adding by and more to of enroll about be end

to question. just Great. Okay. Maybe next my that leads

patient slightly you therapy. of about of us, between versus breakdown from the Regarding would patients, expect and remind be therapy? will to monotherapy the is just XX patients prior type you combination what tumor have in those been additional terms the And enrolled line the XX the different what the

long what you make at, were for control when Sorry key you be the endpoint will looking disease the questions And the go/no-go like or the decision, efficacy PFS? here.

raised. the So I'll try to and that address have questions points all you

and patients going I the think Phase we And adept the that X are changes XX centers new. as to we enrolling enrolling greater more you what as patients XX seeing that a opposed X, is that expect done our number X that for enroll we're be -- to patients to are patients be going and eligible gone of made hybrid to patients to know for units be where have that to will the with are that to Phase highly trial. we would centers community specialized, are have centers academic Phase that sensors between here

types expect across enroll to see tumor And various make. to we're the distribution into. point seeking there we one that's is to that what So

enroll likely individuals, urothelial with cancer, as and cancers lung Some and also help to centers database well. of at centers we're can for that cancer, head example, but those others looking the more for breast are augment our neck

looking -- rates, for is us there, populations. are for that The think, looking efforts this to looking I signal and responders. point, from. comes patient our to response at, at we'll really to at -- look our underrepresented we're targeted try recruitment to goal supplement where strongest those be And we're So obviously, to able be

the have we know, lung that have and melanoma durable. the cancer patients you been As

new notable. ability of of notion that's data the is presenting study we're longer to for see what really on the staying that with today this period But and think is time. disease patients a I control

we'll to analytic incorporating plan So into algorithm. be We on at we're to a point course, component some that of you and principles. update how our of about disease approach going control decision

the patients the as is eligibility of remains planning the So to we're criteria for will and continue time type that see, to as it with remain regards to is being.

individuals really or have So There will much advanced will different. standard that of and for expect be most part, exhausted the out disease. that the will we don't that be either patients have be seeing coming metastatic care

So we to the will be patients continuing as dose to think similar the enrolled today patients enrolled that date. would We're getting those are that to kilogram and these of enrich our per at ones we've XX-milligram cohort. target

then of, generally, also control objectively terms think are reduction or response I tumor line No, to with expect where what cancer, particularly care. think, lung disease could right? take well-established durability patients rate would with the set a setting the bar, then Philippe need or tumor will of where unmet it As depends see and types randomized really a to, high type, our of standard or to those in have I I And whole the on relatively in XX% on lung point And in taking setting a into what that's to think all other some of tumor it Phase top our of are responses we that's it's we these if the there's X Because of see overlay things disease. to interim terms hurdle up response there potential wouldn't what in trial uncommon be? that that, regulatory alluded need, registration. fifth we consideration, not a applying be disease. settings of be where we cancer, any what's entirely end-to-end either But

Got it. Yes.

breakdown to patients what clarify, monotherapy to combination new enrollment? the and is for XX Just therapy between XX the the the

it this would will criteria. the -- So be eligibility obviously

the receive -- those for pembro based pembro regimen, So are, on would on considered the to continue to containing patients label. you pembro that as be indications know,

in we there, there differences you know, monotherapy. earlier of high was on So was with have the these the prevalence data monotherapy, some target based showing various our tumor a And that as types.

the continuing those of not and for on coming it that the should is arm to on that cancer, the carcinoma head the that that triple-negative probably on And the see monotherapy the and would PD-X already to pembro would thinks that brought be I respond, be indicated a would eligibility. not malignancies, breast unlikely monotherapy likely patient will hepatocellular arm and physician appropriate through arm. point that eligibility combination neck be So see those need the on for they urothelial indications combination cancers physician be in the or if had malignancies, out is based criteria. agent esophageal would that the subset malignancies and breast PD-LX we for And pembro if we received whom believes or they'll suitable,

for think of carbo would suggestion even open to activity show think setting with more the cohorts the for FDA Yes. And have we I in we and I likely monotherapy need where pembrolizumab, anyway. single-agent

see think combination So at of we'd probably the those to extent, and I because be want to the monotherapy us FDA own But that use But that's also after. discretion, ovarian, that, to most been have from them point, would would least, some at that patients. basically centers, their choice something colorectal. like some something to more individual is extent, we benefit more contribution this

Canaccord. question comes John of next from Our line of the Newman

for time ongoing the wondering Just XXX, X follow-up how will study currently Phase be allotted. much with

the you'll the rate. doesn't to response term that initially up longer shows Just in like things signal a where able that wondering there's follow for up be perhaps if survival, study show overall

Yes.

that off that are during So we're intervals. Survival once for right data period progression-free patients patients the rates, and we study. looking study collected, is when at collected that event are on is obviously, being occurs now, not but the of follow-up, following is they response come

trial. with survival this that expect be to on would report overall So not we would the something data

the most is stage at treated response and sets of of some to us likely which indication to rate the kind looking X related an the design us for the that where be for control, X and Phase ATRC-XXX, with in trial. that the prioritize disease being study more for driving give idea we're signal what from assessing Phase think formal control way seeing, and would appropriately be treatment what benefit ideally talking I is help and a Phase in X in a fashion, order we John appropriate would effect about, to be controlled was there true

And that data. include Phase survival collecting X could

question comes of Butler the Hutton. next Tony line of from Our EF

rate question in have respectful show therefore, you it. a benefit, to in as where questions tumors, just for to fact, no really if take that's may combination, you those example, remodeled that, that. correctly, the But it's tumor modest that's benefit. preclinical better ATRC-XXX is CRC with that true, response already have get a may is indications that has that's monotherapy, you you combination TME correct I If pembro And be actually do but that of if really be least there I'm certainly, really am in effect, thought you think pembro could this set. if there in of you real and something really indicated. the Or where in So remodeling, in just a And maybe may those correct? demonstrate signals where utilizing there in it an tumors, the demonstrated a opportunity cold about at could related you ovarian out fine, XXX think what I'm -- that. throwing this If was be I'm that and one respectful yet question then, -- here in was than line if, understand CRC the I is true, had is stated comes I microenvironment, that patient late mind so of of directionally from work if for here anything example, notion combination pembro where have some wouldn't really to lot

some don't further you that the then side we have know preclinical I maybe from thoughts. maybe address Yes, want and to if

Tony. Yes,

like agents act you mechanism T is innate right. the that So system, towards immune are directed or In the upstream that of anti-PD-X to inhibitors. on checkpoint PD-LX the if sense cells then

in so normally types. possible. those as all CRC have that tumors an know converting immune tumor principle, you yes, we with don't as that of ATRC-XXX And point is response is that one And out,

From that be Yes. point a clinical think addressing worth at question setting. provocative in would a think, I I very thought some clinical and the

are agents. to think I or think MSI this repair more mismatch individuals PD-X something likely with tumor or concept the cold of likely you something is is respond know, And that a converting that high colon with to cancer cold is -- for I as to pembrolizumab PD-LX a the worth have response of more and sure. investigating

here. Good Thank you raising suggestion, for Tony.

Willey comes of Stifel. line next Our the Stephen from question of

incremental going it expression this And longitudinal set, just patient in asked way time. I've just to stability but you H-Score I'm again. you were look as a expression of data assess target the if to curious somehow think at ask this able before, over I to

So for thank the you question.

we've consent that patients on obtained. We are to And matched that it. analysis, collecting those biopsies for biopsies to longitudinally some for we well do planning are studies

that careful entrances. these -- small As that you that are with conduct. there not to are -- with are is have know, easy numbers, we to be And

final the is We analyze analysis. have baseline plan we at to the what date, To assessments data. and batched the this

serial it sample given first we the and and we the clarity, for So we the progression. And at it go at during disease permission do who those have us not again. just it biopsies the -- during patients cycle for ahead for also baseline, have we do looked do to -- yet at

or disease fit if you the combo patients in there curious patients cohort then mab. And think who know the stable either on the or on if definition the PD-X PD-X either enrolled I cohort stable and/or LX disease targeting Okay. fit some progression or there also eligibility definition. a progression into were the combo just mab a required LX targeting if for incremental I'm

Yes.

an response progression. PD-X PD-LX disease eligibility So agent slightly unsatisfactory is and/or I It's the differently. think or worded criteria while the on

would the for new unsatisfactory the response progressive to and institution disease. was last So therapy. was for we the reason most on looking a that really lack physician, and individuals, the X the of be the of PD-X or PD-LX have the there while of therapy in opinion those What have is, obtained the efficacy at require part,

would at progressive looking those individuals, So most had I that of would say have them disease.

or end Phase headwinds before the to with XX heard lot additional are some to of the XX a Okay. And X year, just as guess, that for companies of to is bit still would decision -- patient in lines? facing, of I the talked that that we've well. amount fungible year-end of know making of and this you've these of little goal about before that incremental site a something other that time data, is I terms from no-go requisite enrolling you XX is of XX kind a an is patients respect But the

you is criteria Well, currently we within study indication. -- final expansion so with and trial as two-stage as set specific know, the a up for

certainly to like you're along way studies begin incorporating the something encouraged think X is health you as is done drug learning what your that most by even you Phase collect and approach by learn companies authorities. and I and early information, about adapting your

that side with adapt information today's about I the fewer have analytics durability think need us either each decisions, notion on allow activity We stabilization prioritize also And patients one had control disease I data response and certainly decisions at of way in of or more we presentation for statistics the but even expand that side of can forward. we indications the the is So a safety to with And drug, we a that's well. is our think pharmacokinetics we not If making as on one early make to based disease of we applying or on as about What the categories. and we approach those we sound in I response. don't at with earlier data. some very think these think looking indications rate, only to trial development, tend today. would bar be we each or important tend control probably looks or learn would using sometimes at modify higher disease new those of of moving look to principles as that, a new bar form planned can for we

Okay. about hard. which interesting that glycan just And These thought that disclosed of these half lastly, targets, I you antibodies perspective just maybe I carbohydrates. against you of was actually then disclosing are been it in of the -- that -- really from mentioned, have conventional the terms immunization you're know kind are as

Just curious from of you class been kind position, you of the puts just around of think has a collaborative target there amount given your interest given to historically? progress where kind just as this

one. so Stephen, take that I'll

a and programs, interest. So obviously. profile we've to number of deal -- Stephen quite proving about is The a we're XXX, discussions of it, in described of as be attractive garnering great

majority the of patients in high even need. great so of colorectal Fv yet been something unmet levels safety signals has far, have cancer a expressed there's You see that's you not potency target And at where binding an the lack optimized. certainly and with yet that

stage. that part They I And peripheral platform is is that might expect. antibodies are There Stephen's of presentation And And this warnings nerve, you're in I not so specific what that they're today couple attack delivering glycans. part commercial black-box what you're problem think reached of you of a have yes, our right. is there example. anti-glycan tumor. the huge hearing for believe It's

find You tricks. can't really through molecular biology

you it do that with and antibody we And out, as can't IgG point simultaneously. they easily nice have very glycans, that just You glycan recognizing specific. are fairly a

the line Dolliver Brookline. final Our comes question of Kemp of from

couple a have questions I of there.

in with in the respectful to regard of enrollment, I'll make assumed what your decision incremental a data the you're be are Some of time. them the to But timeframe be quickly pointed would quick. thinking? cutoff

enroll going study until collect obviously, the so to So to we're fruition. data yes, comes and

think few of I requires the that year end data typically the the and it's will of on able of analyze results it think I our -- weeks when to put cutoff us appropriate most be what for data And together. the to we would up-to-date be. the a report by

able challenges one might alluding response. I important one having think Yes, I is assess and durability maybe sufficient the you to to of be think follow-up that's to, an of

would the by or X not a long-term fairly for than open an or So it easier study stable be bit really of think a disease bit end decision. the Phase more to go when this no-go just think a and give you update seeing go The of based given might try decision in to in program. little decision make little possibly get on don't a I decision to Phase a a no-go the is without be to you would level trigger a to to before a pull want Phase decision that that it regular commitment way to year, indication where we decision lead I of to expensive activity could basically go X move A want patients got forward X overall, on imagine program clinical also And not but the a to you've Phase time making in our enroll a I decision responders decision. you crisp plus/minus But to is business decision making program. it's leave and scenario X. to a a think provide end is

when that the the to decision who by get the all encouraged are PFS to seems responses, patients pretty I that the favor target. next here to us seeing, XX look molecules for there's we're you opportunity think because that months. to important the the an at other we going in I think we a durability of express cost it's have But data feel that also

additional lot. updates Thanks, Okay. Kemp. Well, your in Great. appreciate joining Much look it, and today forward call. for the I everyone, for a thanks future. to the And questions

This Thank Thank for participating. concludes you. today's call. you conference

You may now disconnect.